Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorundrostat - Mineralys Therapeutics

Next Previous
X
Search
Drug Profile

Lorundrostat - Mineralys Therapeutics

Alternative Names: MLS-101; MT-4129

Latest Information Update: 10 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Mineralys Therapeutics; Mitsubishi Tanabe Pharma Corporation
  • Class Acetamides; Amides; Antihypertensives; Benzene derivatives; Cardiovascular therapies; Cyclohexylamines; Small molecules; Triazines
  • Mechanism of Action Aldosterone synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypertension
  • Phase II Renal failure
  • No development reported Cardiovascular disorders

Most Recent Events

  • 08 Jan 2025 US FDA approves IND application for Lorundrostat in Sleep apnoea syndrome and Hypertension
  • 08 Jan 2025 Mineralys Therapeutics plans a phase II trial for Sleep apnoea syndrome in USA
  • 30 Oct 2024 Mineralys Therapeutics completes enrollment in phase III trials in Hypertension (Adjunctive treatment) in USA, Australia, Bulgaria, Canada, France, Germany, Italy, Netherlands, Poland, Puerto Rico, Spain, Romania, UK (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top